Similarly, lower doses of peptide antigen, rather than high doses, preferentially primed high avidity CD4+T cells for cancer immunotherapy, stimulating both antibody responses and cytotoxic T cell responses, instead of skewing the response toward one arm of the immune system [37]. Here, CD4 is linked to cancer.